Lysosomal Storage Diseases: Clinical Trials

138 trials for Lysosomal Storage Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

84 completed, 16 active not recruiting, 10 recruiting, 10 terminated. 138 Phase 3, 34 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3138Completed 84, Active not recruiting 16, Recruiting 10, Terminated 10, Not yet recruiting 5, Unknown 5, Enrolling by invitation 4, Withdrawn 4
Phase 234Completed 15, Active not recruiting 5, Recruiting 4, Terminated 3, Unknown 3, Enrolling by invitation 2, Not yet recruiting 1, Withdrawn 1

Follow Lysosomal Storage Diseases: new trials by email Literature Review of Lysosomal Storage Diseases trials Research Report on Lysosomal Storage Diseases

Trials (filtered) newest first · largest first

All 138 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)
garetosmab - Fibrodysplasia Ossificans Progressiva, FOP
Phase 3Not yet recruitingRegeneron Pharmaceuticals182027-02-022026-11-12
The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric Participants 2 to 11 Years of Age With Gaucher Disease Type 3 (GD3)
Venglustat, Imiglucerase - Gaucher's Disease Type III
Phase 3Not yet recruitingSanofi182026-12-112026-11-10
Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal Disorders
AZ-3102 - Niemann-Pick Disease Type C, GM2 Gangliosidosis
Phase 2 / Phase 3Not yet recruitingAzafaros B.V.2182026-12-102026-10-21
Intracerebroventricular Tralesinidase Alfa in Participants With MPS IIIB (Sanfilippo Syndrome Type B)
Tralesinidase alfa (TA) - MPS IIIB
Phase 3Not yet recruitingSpruce Biosciences142026-12-012026-09-21
A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease
Lucerastat - Fabry Disease
Phase 3RecruitingIdorsia Pharmaceuticals Ltd.162026-12-012026-11-03
Study of Velaglucerase Beta ERT in Children With Gaucher Disease
Velaglucerase beta - Gaucher Disease, Gaucher Disease Type 1
Phase 3Not yet recruitingCANbridge Life Sciences Ltd.102026-09-162026-09-29
A Gaucher Disease Gene Therapy Trial With FLT201
FLT201 - Gaucher Disease Type 1
Phase 3RecruitingSpur Therapeutics452026-04-072026-10-14
Study of Cannabidiol in Sanfilippo Syndrome
Epidiolex, Placebo - Sanfilippo Syndrome, Mucopolysaccharidosis III
Phase 2 / Phase 3RecruitingLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center352026-04-012026-09-15
A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
Migalastat HCl 20 mg - Fabry Disease
Phase 3RecruitingAmicus Therapeutics82026-01-082026-10-22
RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)
RGX-121-3102 - MPS II, Hunter Syndrome (MPS II)
Phase 3Active not recruitingREGENXBIO Inc.22025-11-252026-06-04
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
PRX-102 1 mg/kg every two weeks - Fabry Disease
Phase 2 / Phase 3RecruitingChiesi Farmaceutici S.p.A.222025-07-292026-08-10
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis
AZ-3102, Placebo - Gangliosidoses, GM2, Gangliosidosis, GM1
Phase 3Active not recruitingAzafaros B.V.752025-06-302026-09-22
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis
AZ-3102, Placebo - Niemann-Pick Type C Disease, GM1 Gangliosidosis
Phase 3RecruitingAzafaros B.V.1472025-06-302026-10-27
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)
Nizubaglustat, Placebo - Niemann-Pick Type C Disease
Phase 3RecruitingAzafaros B.V.722025-06-302026-10-28
An Interventional Study of Infigratinib in Children With Hypochondroplasia
infigratinib 0.128 mg/kg/day, infigratinib 0.25 mg/kg/day - Hypochondroplasia
Phase 2 / Phase 3Enrolling by invitationQED Therapeutics, a BridgeBio company242025-04-222026-07-16
An Open Label Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacologic Properties of High Dose Ambroxol Hydrochloride in Adult (≥ 18 Years of Age) Subjects With MPS III
Ambroxol Hydrochloride 30 mg tablet - 9 mg/kg/day, Ambroxol Hydrochloride 30 mg tablet - 18 mg/kg/day, Ambroxol Hydrochloride 30 mg tablet - 27 mg/kg/day - Sanfilippo Syndrome, MPS3
Phase 2 / Phase 3UnknownOzlem Goker-Alpan102024-12-012025-08-20
Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment
Idursulfase-IT, Elaprase - Hunter Syndrome
Phase 2 / Phase 3Active not recruitingTakeda62024-03-052025-11-06
A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT
Experimental: OTL-203, Active Comparator: Allo-HSCT - MPS-IH (Hurler Syndrome)
Phase 3Active not recruitingOrchard Therapeutics412023-12-112025-12-22
A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia
Infigratinib 0.25 mg/kg/day, Placebo Comparator 0.25 mg/kg/day - Achondroplasia
Phase 3CompletedQED Therapeutics, a BridgeBio company1142023-11-102026-03-17
An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3
Gene therapy, Enzyme Replacement Agent - Gaucher Disease, Type 3
Phase 2 / Phase 3WithdrawnAVROBIO2023-10-012023-08-09

Showing 20 of 138. Sign in to see all of them.

Narrower conditions

Fabry Disease (30)  ·  Gaucher Disease (28)  ·  Mucopolysaccharidosis II (19)  ·  Sudden Infant Death (12)  ·  Niemann-Pick Disease, Type C (11)  ·  Glycogen Storage Disease Type II (8)  ·  Mucopolysaccharidosis IV (8)  ·  Mucopolysaccharidosis I (7)  ·  Mucopolysaccharidosis III (7)  ·  Gangliosidosis, GM1 (6)  ·  Rare Diseases (6)  ·  alpha-Mannosidosis (6)  ·  Cystinosis (5)  ·  Gangliosidoses, GM2 (5)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (138)  ·  Nutritional and Metabolic Diseases (138)  ·  Metabolism, Inborn Errors (137)  ·  Genetic Diseases, Inborn (135)  ·  Metabolic Diseases (133)  ·  Nervous System Diseases (102)  ·  Brain Diseases (85)  ·  Brain Diseases, Metabolic (85)  ·  Brain Diseases, Metabolic, Inborn (85)  ·  Central Nervous System Diseases (85)  ·  Lysosomal Storage Diseases, Nervous System (85)  ·  Lipid Metabolism Disorders (78)  ·  Lipid Metabolism, Inborn Errors (78)  ·  Lipidoses (78)

Interventions

migalastat (12)  ·  imiglucerase (8)  ·  larazotide acetate (8)  ·  Glucosylceramidase (7)  ·  agalsidase alfa (7)  ·  agalsidase beta (7)  ·  miglustat (7)  ·  idursulfase (6)  ·  taliglucerase alfa (6)  ·  2-Hydroxypropyl-beta-cyclodextrin (5)  ·  GAA protein, human (5)  ·  eliglustat (5)  ·  Cysteamine (4)  ·  venglustat (4)  ·  Cyclodextrins (3)

Sponsors

Genzyme, a Sanofi Company (15)  ·  Shire (14)  ·  Amicus Therapeutics (11)  ·  Chiesi Farmaceutici S.p.A. (7)  ·  Sanofi (6)  ·  BioMarin Pharmaceutical (5)  ·  Pfizer (5)  ·  Amgen (4)  ·  Azafaros B.V. (4)  ·  JCR Pharmaceuticals Co., Ltd. (4)  ·  Mandos LLC (4)  ·  Protalix (4)  ·  Ultragenyx Pharmaceutical Inc (4)  ·  ISU Abxis Co., Ltd. (3)  ·  Idorsia Pharmaceuticals Ltd. (3)

Countries

United States (87)  ·  United Kingdom (66)  ·  France (51)  ·  Spain (45)  ·  Italy (42)  ·  Canada (41)  ·  Germany (39)  ·  Australia (36)  ·  Argentina (29)  ·  Brazil (27)  ·  Netherlands (26)  ·  Japan (23)  ·  Turkey (Türkiye) (21)  ·  Poland (19)  ·  Belgium (16)

Top investigators

Allan M Lund, MD (2)  ·  Debra Lounsbury (2)  ·  Paul Harmatz, MD (2)  ·  Alexander Schramm (1)  ·  Ali Rabani, Professor (1)

Results publications

PMID 33874971, PMID 27839979, PMID 39847314, PMID 19775921, PMID 26053270, PMID 27509102, PMID 27657681, PMID 31889231, PMID 32063397, PMID 32994552, PMID 35961250, PMID 37415957, PMID 37915038, PMID 39774103, PMID 41631150, PMID 18729283, PMID 19117887, PMID 20393176, PMID 20730727, PMID 21150784, PMID 21543987, PMID 21586746, PMID 21900191, PMID 22476655, PMID 22929184, PMID 23270487, PMID 23339116, PMID 23531228, PMID 23837440, PMID 24948347, PMID 24950666, PMID 24993530, PMID 25487082, PMID 25688781, PMID 25795794, PMID 25801797, PMID 25819691, PMID 25955246, PMID 26043810, PMID 26185417, PMID 27102949, PMID 27174694, PMID 27241455, PMID 27499018, PMID 27834756, PMID 27839981, PMID 27955919, PMID 28167660, PMID 28535791, PMID 29248359

NIH funding

2015 (5), 2023 (5), 2019 (4), 2008 (3), 2009 (3), 2014 (2), 2018 (2), 2004 (1), 2005 (1), 2016 (1), 2017 (1), 2025 (1)